Abcam plc.

In the top M&A by deal value, Danaher Corp. entered into a definitive agreement to acquire Abcam plc. for $24.00 per share in cash, or a total enterprise value of approximately $5.7bn including as

Twelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Amgen, Plexium Team Up Against Challeng

Medical Device Acquisitions The third quarter featured 21 device M&A transactions, 10 of which had disclosed values that together totaled $7.1bn, versus the second quarter, when 14 deals totaled $2bn.